Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme

被引:124
作者
Anttila, Ahti [1 ]
Kotaniemi-Talonen, Laura [1 ]
Leinonen, Maarit [1 ]
Hakama, Matti [1 ]
Laurila, Pekka [2 ]
Tarkkanen, Jussi [2 ]
Malila, Nea [1 ,3 ]
Nieminen, Pekka [4 ,5 ]
机构
[1] Finnish Canc Registry, Mass Screening Registry, FIN-00130 Helsinki, Finland
[2] HUSLAB Katiloopisto Pathol Lab, Helsinki, Finland
[3] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland
[4] Univ Helsinki, Cent Hosp, Dept Obstet & Gynaecol, Helsinki, Finland
[5] Finnish Canc Soc, Pathol Lab, Helsinki, Finland
来源
BMJ-BRITISH MEDICAL JOURNAL | 2010年 / 340卷
基金
芬兰科学院;
关键词
HUMAN-PAPILLOMAVIRUS; CONVENTIONAL CYTOLOGY; FINLAND;
D O I
10.1136/bmj.c1804
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the performance and impact of primary human papillomavirus (HPV) DNA screening with cytology triage compared with conventional cytology on cervical cancer and severe pre-cancerous lesions. Design Randomised trial. Setting Population based screening programme for cervical cancer in southern Finland in 2003-5. Participants 58 076 women, aged 30-60, invited to the routine population based screening programme for cervical cancer. Interventions Primary HPV DNA test (hybrid capture II) with cytology triage if the result was positive or conventional cytological screening (reference). Main outcome measures Rate of cervical cancer, cervical intraepithelial neoplasia (CIN) grade III, and adenocarcinoma in situ (as a composite outcome referred to as CIN III+) during 2003-7 through record linkage between files from the screening registry and the national cancer registry. Results In the HPV and conventional arms there were 95 600 and 95 700 woman years of follow-up and 76 and 53 cases of CIN III+, respectively (of which six and eight were cervical cancers). The relative rate of CIN III+ in the HPV arm versus the conventional arm was 1.44 (95% confidence interval 1.01 to 2.05) among all women invited for screening and 1.77 (1.16 to 2.74) among those who attended. Among women with a normal or negative test result, the relative rate of subsequent CIN III+ was 0.28 (0.04 to 1.17). The rate of cervical cancer between arms was 0.75 (0.25 to 2.16) among women invited for screening and 1.98 (0.52 to 9.38) among those who attended. Conclusions When incorporated into a well established organised screening programme, primary HPV screening with cytology triage was more sensitive than conventional cytology in detecting CIN III+ lesions. The number of cases of cervical cancer was small, but considering the high probability of progression of CIN III the findings are of importance regarding cancer prevention.
引用
收藏
页数:8
相关论文
共 20 条
[1]  
[Anonymous], IARC WHO HDB CANC PR
[2]   Cervical cancer screening programme in Finland [J].
Anttila, A ;
Nieminen, P .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (17) :2209-2214
[3]   Alternative technologies in cervical cancer screening: a randomised evaluation trial [J].
Anttila, Ahti ;
Hakama, Matti ;
Kotaniemi-Talonen, Laura ;
Nieminen, Pekka .
BMC PUBLIC HEALTH, 2006, 6 (1)
[4]  
Arbyn M., 2008, European guidelines for quality assurance in cervical cancer screening, Second Edition"
[5]   Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial [J].
Bulkmans, N. W. J. ;
Berkhof, J. ;
Rozendaal, L. ;
van Kemenade, F. J. ;
Boeke, A. J. P. ;
Bulk, S. ;
Voorhorst, F. J. ;
Verheijen, R. H. M. ;
Groningen, Kvan ;
Boon, M. E. ;
Ruitinga, W. ;
van Ballegooijen, M. ;
Snijders, P. J. F. ;
Meijer, C. J. L. M. .
LANCET, 2007, 370 (9601) :1764-1772
[6]   Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study [J].
Dillner, Joalim ;
Rebolj, Matejka ;
Birembaut, Philippe ;
Petry, Karl-Ulrich ;
Szarewski, Anne ;
Munk, Christian ;
de Sanjose, Silvia ;
Naucler, Pontus ;
Lloveras, Belen ;
Kjaer, Susanne ;
Cuzick, Jack ;
van Ballegooijen, Marjolein ;
Clavel, Christine ;
Iftner, Thomas .
BRITISH MEDICAL JOURNAL, 2008, 337 (7676) :a1754
[7]  
*FINN CANC REG I S, 2009, CANC SOC FINL PUBL, V76
[8]  
International Agency for Research on Cancer, 2007, IARC MON EV CARC RIS, V90
[9]   The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice [J].
Khan, MJ ;
Castle, PE ;
Lorincz, AT ;
Wacholder, S ;
Sherman, M ;
Scott, DR ;
Rush, BB ;
Glass, AG ;
Shiffman, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (14) :1072-1079
[10]   HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial [J].
Kitchener, Henry C. ;
Almonte, Maribel ;
Thomson, Claire ;
Wheeler, Paula ;
Sargent, Alexandra ;
Stoykova, Boyka ;
Gilham, Clare ;
Baysson, Helene ;
Roberts, Christopher ;
Dowie, Robin ;
Desai, Mina ;
Mather, Jean ;
Bailey, Andrew ;
Turner, Andrew ;
Moss, Sue ;
Peto, Julian .
LANCET ONCOLOGY, 2009, 10 (07) :672-682